Phase II open-label safety study of accelerated Allergovit Birch dose escalation

Phase 2, open-label trial of birch pollen allergoid in seasonal allergic rhinitis (SAR) and allergic rhinoconjunctivitis (ARC) (2 arms), sponsored by Allergopharma. Primary endpoints: Safety and tolerability of accelerated dose escalation with 4 injections of Allergovit Birch and Safety and tolerability of accelerated dose escalation with 7 injections of Allergovit Birch. Started May 2016; status: completed.